Momenta Pharmaceuticals' Management Presents At Barclays Capital 2012 Global Healthcare Conference (Transcript)

Momenta Pharmaceuticals, Inc. (MNTA)

Barclays Capital 2012 Global Healthcare Conference

March 14, 2012 2:30 PM ET

Executives

Rick Shea – Chief Financial Officer

Analysts

Doug Gale – Senior Analyst, Barclays Capital

Presentation

Doug Gale

Compare to:
Previous Statements by MNTA
» Momenta Pharmaceuticals CEO Presents at 2012 Citi Global Health Care Conference (Transcript)
» Momenta Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Momenta Pharmaceuticals CEO Hosts Investor Conference Call to Discuss Follow-On Biologics Collaboration with Baxter (Transcript)
» Momenta Pharmaceuticals' Management Presents at Deutsche Bank BioFEST 2011 - Event Transcript

Good afternoon. My name is Doug Gale I cover Biotech Pharma at Barclays Capital as part of the life sciences team. I’m trying to do it in sort of integrated basis. Up next we have Momenta Pharmaceuticals represented by its CFO Rick Shea.

Clearly a company that is I think really interesting from both technology stand point as well as no shortage of news flow and excitement in the industry. Covering generics manufacturer or generics industry as a whole though I know Momenta is not a generics company, but it certainly has a lot of the elements of litigation and patent challenges that bring a lot of the intrigue and usually attracts a lot of best interest.

So perhaps at the start I think what I thought would be helpful for some people to sort of explain exactly how you define yourself as a company. And what did exactly is that you do and your platform for development of both biosimilars or you know biobetters I think you would even perhaps argue as well as potentially novel therapeutics?

Rick Shea

Okay Doug thanks very much by the way for inviting us. And what we like to say Momenta is a biotechnology company that happens to be working on developing and commercializing generic products, follow on biosimilar or bioequivalent products as well as novel products. And our aim has always been to balance the work that we are doing in the generic programs with moving forward with novel drugs as well. So I think when we first emerged back as we are going public 2004 we were thought of as a sugar company, complex sugars, heparins, polysaccharides. And we’ve also been thought of as a characterization company, a company that was good at figuring out the structure, the chemical structure of complex mixture products.

1 2 3 Next › Last »